Cytokinetics Inc - Company Profile
Powered by 
All the sales intelligence you need on Cytokinetics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cytokinetics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cytokinetics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cytokinetics Inc (Cytokinetics) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. The company's main activities involve research and development of small molecule drug candidates targeting muscle function and contractility. Cytokinetics' major products include investigational medicines aimed at treating cardiovascular and neuromuscular diseases characterized by impaired muscle function. It is also developing Muscle biology-directed research, neuromuscular, cardiac myosin activators, and additional skeletal muscle activators. The company is developing aficamten, a next-generation cardiac myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM). It operates through a network of research collaborations and partnerships to advance its drug candidates. The company operates in the US and Europe. Cytokinetics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
350 Oyster Point Boulevard, South San Francisco, California, 94080
Website
www.cytokinetics.com
Telephone
1 650 6243000
No of Employees
673
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CYTK (NASD)
Revenue (2024)
$88.0M
376.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-33.2%
(2024 vs 2023)
Market Cap*
$11.5B
Net Profit Margin (2024)
XYZ
72.1%
(2024 vs 2023)
* As of and is in US$
Cytokinetics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline - |
| Omecamtiv Mecarbil: Heart Failure with Reduced Ejection Fraction |
| Aficamten: Obstructive Hypertrophic Cardiomyopathy, Pediatric oHCM, nHCM |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In June, the company introduced MYQORZO (aficamten) in Germany to treat patients with symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. |
| 2026 | Regulatory Approval | In February, the company received European Commission approval for MYQORZO (aficamten) to treat adults with symptomatic obstructive hypertrophic cardiomyopathy. |
| 2026 | Regulatory Approval | In January, the company received approval from the US Food and Drug Administration for MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. |
Competitor Comparison
| Key Parameters | Cytokinetics Inc | Merck & Co Inc | AstraZeneca Plc | Novartis AG | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | Germany |
| City | South San Francisco | Rahway | Cambridge | Basel | Leverkusen |
| State/Province | California | New Jersey | Cambridgeshire | Basel-Stadt | Nordrhein-Westfalen |
| No. of Employees | 673 | 75,000 | 96,100 | 75,267 | 87,757 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John T. Henderson | Chairman | Executive Board | 2022 | 80 |
| Robert I. Blum | Chief Executive Officer; President; Director | Executive Board | 2007 | 62 |
| Sung H. Lee | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | 55 |
| Kari K. Loeser | Chief Compliance Officer; Vice President | Senior Management | 2021 | - |
| Stuart Kupfer, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer